Summit Therapeutics plc
('Summit', 'the Company')
SUMMIT ANNOUNCES CHANGE OF REGISTERED COMPANY ADDRESS
Oxford, UK, 30 March 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that the registered office address of the Company has changed to 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, UK with immediate effect.
All other details remain the same including the Company's website (www.summitplc.com), telephone number (+44 (0) 1235 443 939) and fax number (+44 (0) 1235 443 999).
This announcement has been made in accordance with Rule 17 of the AIM Rules for Companies.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7213 0880 |
-END-